Abstract
Current anti-seizure drugs (ASDs) are believed to reduce neuronal excitability through modulation of ion channels and transporters that regulate excitability at the synaptic level. While most patients with epilepsy respond to ASDs, many remain refractory to medical treatment but respond favorably to a high-fat, low-carbohydrate metabolism-based therapy known as the ketogenic diet (KD). The clinical effectiveness of the KD has increasingly underscored the thesis that metabolic factors also play a crucial role in the dampening neuronal hyperexcitability that is a hallmark feature of epilepsy. This notion is further amplified by the clinical utility of other related metabolism-based diets such as the modified Atkins diet and the low-glycemic index treatment (LGIT). Traditional high-fat diets are characterized by enhanced fatty acid oxidation (which produces ketone bodies such as beta-hydroxybutyrate) and a reduction in glycolytic flux, whereas the LGIT is predicated mainly on the latter observation of reduced blood glucose levels. As dietary implementation is not without challenges regarding clinical administration and patient compliance, there is an inherent desire and need to determine whether specific metabolic substrates and/or enzymes might afford similar clinical benefits, hence validating the concept of a “diet in a pill.” Here, we discuss the evidence for one glycolytic inhibitor, 2-deoxyglucose (2DG) and one metabolic substrate, β-hydroxybutyrate (BHB) exerting direct effects on neuronal excitability, highlight their mechanistic differences, and provide the strengthening scientific rationale for their individual or possibly combined use in the clinical arena of seizure management.
Key Points
- •
Cellular metabolism plays a key role in the modulation of neuronal excitability.
- •
2-Deoxyglucose (2DG), an inhibitor of glycolysis, abrogates seizure activity and retards epilepsy progression both in vitro and in vivo.
- •
Beta-hydroxybutyrate (BHB), a by-product of fatty acid oxidation, exerts both anti-seizure and neuroprotective effects.
- •
2DG and BHB offer potential novel avenues for suppressing seizure activity and possibly epileptogenesis.
Introduction
For decades, the mechanistic focus in the field of epilepsy research has been on ion channels and transporters that regulate neuronal excitability at the synapse. Indeed, virtually all anti-seizure drugs (ASDs) are believed to exert their clinical effects on synaptic targets, whether at the pre- or post-synaptic terminals (Rogawski et al., 2016). However, it has become increasingly clear that metabolic factors can potently affect neuronal excitability and even influence the activity of key cellular membrane-bound ion channels such as inhibitory adenosine and GABAA receptors and ATP-sensitive potassium (KATP) channels (Reid et al., 2014; ). The steadily increasing scientific arena of metabolic control of neuronal excitability has been catalyzed by the clinical success and evidence-based validation of the high-fat, low-carbohydrate ketogenic diet (KD) and its variants [i.e., medium-chain triglyceride (MCT), modified Atkins diet (MAD), and low-glycemic index treatment (LGIT)] (; Rho and Stafstrom, 2012; ; ). While the fundamental mechanisms underlying the efficacy of these metabolic treatments across numerous epileptic conditions remain unclear, there is growing evidence that specific metabolic substrates and enzymes may act directly or indirectly to induce anti-seizure (and even neuroprotective) effects. Moreover, substrate or pharmacological modulation of key biochemical pathways has shown similar benefits (Rogawski et al., 2016).
Inhibition of Glycolysis
The KD originated from the centuries-old observation that fasting led to seizure control and was thus formulated to mimic the physiological effects of fasting (). Clinicians also noted that seizure control while on the KD could be abruptly lost when carbohydrates, which would break the ketosis, were ingested (). This observation led to the general hypothesis that carbohydrate restriction alone might protect against seizure activity (). Further amplifying this idea was the growing notion that reducing total calorie intake per se could also suppress seizures and provide neuroprotection (; ; Yuen and Sander, 2014; ).
Glucose is an obligate energy source for the brain, which is a highly energy-dependent organ, consuming approximately 20% of the body’s total caloric requirements at rest (). Seizure activity places further demands on the overall brain metabolic milieu due to excessive neuronal activity – reflected by the aberrant high-voltage activity seen from single neurons to brain networks using microelectrodes and extracellular field and surface scalp electrodes. Neurometabolic coupling during seizure activity not only depends on energy metabolism of neurons, but may also involve astrocytes as they may provide neurons with fuel (i.e., lactate) through the lactate shuttle (; ; , but see ). In addition, brain microvasculature integrity is of paramount importance in supporting the neurometabolic fluctuations required to enable neuronal excitability (). Not surprisingly then, deficits in glucose availability and usage have been linked to several neurological disorders (). By contrast, enhanced neuronal activity, such as during epileptic seizures, significantly increases regional blood glucose utilization, as shown by human positron emission tomography (PET) studies (), thus suggesting a rationale for potential seizure control through metabolic interventions.
2-Deoxyglucose, A Glycolysis Inhibitor
As mentioned above, the KD mimics fasting in restricting the intake of the main source of brain energy (i.e., carbohydrates) while supplying fat and protein to generate ketone bodies as an alternative energy source. While the mechanisms of seizure control by the KD are likely to be multi-faceted (), it is important to note that the KD bypasses glycolysis, and an intake of even a small amount of sugar quickly reverses its otherwise seizure-stabilizing effects (). This suggests that energy production by glycolysis may be important for seizure activity and bypassing or suppressing glycolysis may represent a key mechanism involved in KD treatment. Collectively, these observations provide the rationale for the notion that inhibitors of glycolysis may mimic in part the therapeutic effects of the KD. It is also well known that ketolysis itself decreases glycolytic flux, and it has been proposed that ketone bodies attenuate neuronal cellular excitability through this mechanism (). As there are known agents that restrict glycolytic flux, this overarching hypothesis is eminently testable.
One promising glycolysis inhibitor for seizure protection is the glucose analog 2-deoxyglucose (2DG) which differs from glucose by the substitution of oxygen from the 2′ position (Figure 1). Similar to glucose, 2DG is transported into cells and is phosphorylated to 2DG-6-phosphate at the 6′ position by hexokinase (HK), but this phosphorylated substrate cannot be converted to fructose-6-phosphate by phosphoglucose isomerase (PGI), and is thus trapped in the cell. The accumulation of 2DG-6-phosphate competitively inhibits the rate-limiting enzymes, primarily PGI (Wick et al., 1957) but also HK (), hence partially blocking glycolysis. In addition, inhibition of PGI would divert glycolysis to the pentose phosphate pathway (PPP), producing ribulose and glutathione. It should be kept in mind that 2DG, like glucose, is not only taken up by neurons (via glucose transporter 3) but is also taken up by glial cells (via glucose transporter 1), inhibiting astrocytic glycolysis. Recent studies hypothesize that astrocytes may transport their glycolytic end-product, lactate, as an alternative fuel source to neurons through the “astrocyte-neuron lactate shuttle” (ANLS) (, but see ). Therefore, 2DG may potentially affect neuronal activity indirectly by suppressing astrocytic glycolysis. This biochemical feature has been successfully exploited to identify energetically active cells, notably hyperexcitable brain cells or rapidly dividing cancer cells (; ). Cancer cells, even in aerobic conditions, tend to use glycolysis for energy production over oxidative phosphorylation (Warburg effect); 2DG enhances oxidative phosphorylation, countering the Warburg effect (). For decades, fluorinated 2DG (18F-2DG) has been safely used as a tracer to reveal regional glucose utilization by PET (Wree, 1990; ).
Figure 1
With respect to epilepsy, 2DG has been shown to exert broad activity in several in vitro and in vivo models of acute seizures (Stafstrom et al., 2009). In vitro, 2DG attenuates high-frequency epileptiform bursting in the high extracellular potassium model, and in response to two chemoconvulsants – 4-aminopyridine (4-AP, a non-selective potassium channel blocker) and bicuculline [a γ-aminobutyric acid (GABAA) receptor antagonist] (Stafstrom et al., 2009). 2DG was also effective in hippocampal brain slices whether synaptic activity in CA3 pyramidal neurons was left intact or blocked by AMPA, NMDA, and GABAA receptor antagonists (DNQX, APV, and bicuculline, respectively) (Shao and Stafstrom, 2017). Interestingly, CA3 neuronal firing persisted even after intracellular administration of 2DG, suggesting that glycolytic inhibition of individual neurons is not sufficient to stop neuronal firing. Indeed, bath application of 2DG in hippocampal slices abolished epileptiform bursts induced by a Mg2+-free medium containing 4-AP in a dose-dependent manner (Shao and Stafstrom, 2017). Collectively, these results indicate that 2DG can markedly block epileptiform activity in both interictal and ictal states. Recently, however, a study reported that 2DG reduced Cs+- and bicuculline-induced interictal-like activity while increasing ictal-like activity in rat hippocampal slices (). The precise reasons for this discrepancy are unclear. Possibly, in most of the aforementioned in vitro seizure models, either K+ channel or GABAergic inhibition is unaffected, whereas in the model used by , both inhibitory mechanisms are blocked, which may hamper seizure termination.
The anti-seizure effects of 2DG were also demonstrated in different types of animal models of seizures. 2DG increased the mean after-discharge threshold in the rat perforant path kindling model (; Stafstrom et al., 2009). Further, 2DG blocked seizure activity in the 6-Hz corneal stimulation model (; Stafstrom et al., 2009; ) and in Frings audiogenic seizure-susceptible mice (Stafstrom et al., 2009). In addition, 2DG significantly delayed seizure onset and diminished seizure severity and duration in the pilocarpine model, and delayed seizure onset in the kainate (KA) model (). In contrast, 2DG was unable to protect against seizures induced by pentylenetetrazol (PTZ) or maximal electroshock (MES) (). While 2DG’s spectrum of activity was not universal in some standard experimental models, its profile has certainly been shown to be unique compared to existing anti-seizure medications. Another important aspect of 2DG function deserves mention – 2DG is mostly taken up by cells that are metabolically active. This use-dependence affords a distinct advantage for any therapeutic strategy aimed at targets in brain areas exhibiting hyperexcitable and hypersynchronous discharge, as seen with epileptic seizures.
The acute and chronic effects of 2DG in different model systems are likely due to distinct cellular and molecular mechanisms. With respect to anti-epileptogenesis as reflected in the rat kindling model, the most intriguing mechanism reported is 2DG’s actions in decreasing brain-derived neurotrophic factor (BDNF) and its receptor trkB (), both of which are necessary for kindling to occur (). Specifically, these changes are mediated by the transcriptional repressor Neuron Restrictive Silencing Factor (NRSF) and its co-repressor, the nicotinamide adenine dinucleotide hydride (NADH)-sensitive carboxy-terminal binding protein (CtBP), which together target the promoter regions of both Bdnf and TrkB genes (). There is growing evidence that repression of BDNF and trkB retards kindling progression, and this may be the key mechanism underlying the anti-epileptogenic effects of 2DG (; ; ). An additional mechanism implicated in 2DG action is upregulation of mRNAs of the ATP-sensitive potassium (KATP) channel subunits Kir6.1 and Kir6.2 (Yang et al., 2013). Plasmalemmal KATP channels, when open and thus allowing potassium efflux, hyperpolarize the membrane. 2DG may also modulate GABAergic signaling, specifically by potentiating extra-synaptic tonic GABAergic currents through activation of neurosteroidogenesis ().
Other than its anti-seizure activity, 2DG has also been shown to be neuroprotective. Specifically, 2DG protected against the deleterious oxidative and metabolic effects of kainic acid in rat hippocampal cell cultures by enhancing stress responses () and reduced seizure occurrence in the mouse bilateral carotid artery occlusion model (Redjak et al., 2001). These neuroprotective actions may result from possible enhancement of PPP flux which provides endogenous antioxidant glutathione, but also appear to involve mechanisms distinct from direct glycolytic restriction, including reduced oxidative stress through ketogenesis and sustaining mitochondrial function (Yao et al., 2011) and activation of adenosine monophosphate (AMP)-activated protein kinase which confer resistance to oxidative stress ().
Notably, other researchers reported that 2DG might exert pro-seizure/pro-epileptogenic effects under certain conditions, which adds to the complexity of 2DG action. One study observed that the latency to seizure onset was decreased after 2DG administration in the PTZ and kainate models (but prolonged in the 6 Hz model) (). While the mechanism(s) underlying these findings remain(s) unclear, 2DG is known to increase cerebral blood flow (), so it is possible that seizure activity might be promoted acutely as initial neuronal and network excitability is fueled, which may confound the interpretation of these findings. More recently, it was reported that daily intracerebroventricular administration of 2DG for 4 weeks resulted in spontaneous seizures in two of ten rats and a depolarized GABA equilibrium potential (EGABA) suggesting a pro-epileptogenic effect, although the acute effects of 2DG were more complex (i.e., decreased synaptic excitability but depolarized membrane potential and EGABA) (Samokhina et al., 2017). It is not known what underlies the discrepancies seen with 2DG in different seizure models, and between acute and chronic treatment protocols with 2DG. Clearly, more studies are needed to resolve these differences and to further understand the effects of 2DG, and more broadly metabolic interventions for seizures/epilepsy.
Ketone Bodies as Anti-Seizure Agents
While the efficacy of the KD in patients with medically intractable epilepsy is no longer debatable (; , ; ), the mechanisms underlying its clinical effects remain unclear. Many hypotheses have been advanced, including but not limited to favorable changes in neurotransmitter systems (e.g., GABA, glutamate, and adenosine), glycolytic restriction/diversion, enhancement of tricarboxylic acid (TCA) cycle function, improved cellular bioenergetics and mitochondrial function (with decreased oxidative stress), and direct inhibitory effects of fatty acids (Rogawski et al., 2016).
The hallmark feature of the KD is the production of ketone bodies (KB) [i.e., β-hydroxybutyrate (BHB), acetoactate (ACA) and acetone] through fatty acid oxidation primarily in the liver, and possibly the brain (). Ordinarily, fatty acids are converted to acetyl-CoA which then enters the TCA cycle. However, when fatty acid levels rise and exceed maximal TCA cycle capacity – as in the case with KD treatment – acetyl-CoA is shunted to ketogenesis. Acetoacetyl-CoA is produced from two acetyl-CoA molecules through a thiolase enzyme and is then is used for the synthesis of ACA which is interconverted with BHB through a dehydrogenase enzyme. Acetone is a spontaneous decarboxylation product of ACA and is eliminated primarily through the lungs and kidneys. BHB and ACA are transported to the brain interstitial space via monocarboxylic acid transporters (MCTs) and enter mitochondria which convert these ketone bodies to acetyl-CoA through several enzymatic steps. The reconstituted acetyl-CoA species are then utilized by the TCA cycle for ATP production. Increased ATP production can then lead to further biochemical and physiological effects that can contribute to seizure control and neuroprotection (see below).
In this regard, a persistent question has been whether ketone bodies are direct mediators; that is, do ketone bodies exert biological effects that attenuate neuronal hyperexcitability and/or synchrony, beyond their classic role as fuel for ATP production? The common belief is that they do not, based on clinical studies demonstrating that blood levels of ketone bodies do not correlate well with seizure control (; van Delft et al., 2010). Additionally, the mechanistic role for KB is most seriously challenged when considering the low-glycemic index therapy (LGIT) which is an effective treatment for intractable forms of epilepsy but is not associated with significant elevations in blood ketone levels (Pfeifer and Thiele, 2005). Thus, the LGIT must work through distinct mechanisms that have yet to be fully elucidated but may involve KATP channels and adenosine receptors (; ).
At least in experimental models, ketosis does not appear to be necessary for seizure control (Thavendiranathan et al., 2000; ). For example, a MCT KD was unable to block seizures induced by MES, threshold electroconvulsive shock, threshold PTZ and maximal PTZ, despite significant elevations in blood ketone levels (Thavendiranathan et al., 2000). Moreover, a nutritional strategy targeting specific amino acids, fatty acids and carbohydrates constituting a low ketogenic ratio (i.e., the ratio of fat to carbohydrate plus protein by weight) without significant ketosis still resulted in seizure protection in the kainic acid mouse model of epilepsy (). It should be noted that the study utilized MCTs (i.e., decanoate) that are known to directly block α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (). Thus, while various dietary approaches may all work to control epileptic seizures, the underlying mechanisms are likely distinct, making it somewhat difficult to compare these with the classic or even modified KD.
Notwithstanding these clinical and laboratory observations, more recent clinical data suggest otherwise (; ) and the growing mechanistic properties of ketone bodies strengthen the biological plausibility that these substrates afford both structural and functional neuroprotection in the epileptic brain. In a prospective pilot clinical study of children with medically intractable epilepsy who were treated with the KD, blood BHB levels determined by tandem mass spectrometry were inversely related to seizure frequency (). This is consistent with an earlier report that blood ketone levels (i.e., BHB) correlated better with seizure control than urine ketone levels (i.e., ACA) ().
The earliest laboratory reports of ketone bodies exerting anti-seizure effects came in the early 1930s, shortly after the introduction of the KD in clinical practice (, , , ). Specifically, ACA was shown to protect against seizures induced by thujone, a constituent of wormwood oil later shown to be an antagonist of GABAA receptors (). Decades later, acetone was shown to provide dose-dependent beneficial effects in the MES, subcutaneous PTZ, amygdala kindling, and the AY-9944 (an inhibitor of cholesterol biosynthesis, which evokes atypical absence seizures) models of induced seizures or epileptogenesis (). Further, in support of Keith’s original studies, ACA was effective in blocking seizures in a model of sensory-evoked reflex seizures, the Frings audiogenic seizure-susceptible mice (Rho et al., 2002). More recently, several research teams demonstrated that BHB, when administered acutely or chronically, conferred seizure protection in immature rat pups against flurothyl-induced () and in the rat betamethasone-NMDA model of infantile spasms (Yum et al., 2015). In another study, using the clinically relevant Kcna1-null mouse model of developmental limbic epilepsy (that lacks the delayed rectifier voltage-gated potassium channel α subunit), found that BHB afforded the same degree of seizure control as the full KD. Taken together, these and other studies support the hypothesis that KB can themselves induce anti-seizure effects separate from their role in ATP production. Hence, the possibility that these compounds contribute directly to the clinical effects of the KD cannot be readily dismissed.
So, what are the key molecular targets of ketone body action? As KB were historically viewed as metabolic substrates and not direct modulators of synaptic function, it was not surprising that low millimolar concentrations of BHB and ACA did not influence the activity of GABAA receptors, ionotropic glutamate receptors, or voltage-gated sodium channels in normal rodent hippocampus (Thio et al., 2000; Yang et al., 2007), in contrast to our current understanding of how most of clinically approved ASDs work (Rogawski et al., 2016). However, in a more elegant study, it was shown that neuronal excitability could be suppressed by ketone bodies through a pre-synaptic mechanism (). Specifically, BHB and ACA inhibited the presynaptic release of glutamate by directly competing with Cl- at the allosteric modulation site on vesicular glutamate transporters (VGLUTs). These investigators also demonstrated that the proconvulsant effects of 4-AP, accompanied by presynaptic release of glutamate, could be attenuated by ACA ().
The first mechanistic insights into KB action, however, came from neurochemical experiments in the 1990s. and demonstrated that ketone bodies (i.e., BHB) altered glutamate metabolism within the tripartite neurovascular unit, comprising neurons, astrocytes and the capillary microvasculature. In the ketotic state, the aspartate-to-glutamate ratio is reduced based on a change in the equilibrium of the aspartate aminotransferase reaction. As the transamination of glutamate to aspartate is decreased, glutamate decarboxylation to GABA is increased (; ). Thus, increased synaptic levels of GABA would enable increased inhibitory neurotransmission and dampen seizure activity. While this has long stood as a rational and intuitive mechanistic argument, supported by predicted neurochemical changes in certain brain regions but not the key seizure-prone areas such as the neocortex or hippocampus, more direct evidence has not been forthcoming (Yudkoff et al., 2001; , ; Valente-Silva et al., 2015; Zhang et al., 2015). Further, the GABAergic hypothesis of ketone body action doesn’t explain why the KD would be effective in blocking seizure activity in patients with epilepsy who were refractory to GABAergic medications ().
A generation ago, it was speculated that KATP channels might be an important link between cellular energy metabolism and plasmalemmal membrane excitability (Schwartzkroin, 1999). Indeed, it has long been known that KATP channels are activated when the intracellular ATP-to-ADP ratio falls, resulting in efflux of potassium and hence causing membrane hyperpolarization. However, it was not until much later that demonstrated that ketone bodies influence the activity of KATP channels. Using brain slices from normal and genetically engineered mice that lack KATP channels, they showed that BHB and ACA decreased the spontaneous firing of GABAergic interneurons in the substantia nigra pars reticulata (a subcortical modulator of seizure propagation), and that this effect was dependent on KATP channels and GABAB receptors (). The central thesis has been that ATP levels subjacent to cell membrane-bound KATP channels are depleted due to heightened neuronal excitability during seizure activity which requires energy, and this would lead to activation of inhibitory KATP channels.
Despite its intrinsic appeal, there is yet no direct confirmation of this mechanistic hypothesis. Moreover, the KD and ketone bodies have been shown to increase cellular levels of ATP via enhanced mitochondrial biogenesis and respiration (; ; ). Another explanation for ketone body action on KATP channels was provided by who showed that low-glucose conditions lead to opening of pannexin channels and efflux of ATP through these channels on CA3 pyramidal neurons, subsequent conversion of ATP to adenosine via extracellular ectonucleotidases, and activation of adenosine A1 inhibitory receptors, which are coupled to KATP channels (). Thus, BHB might induce a form of autocrine regulation by enhancing ATP synthesis, with one downstream consequence being cellular membrane inhibition.
Other novel targets for ketone body action have been described in recent years. In the study by mentioned above, BHB-induced block of spontaneous recurrent seizures in Kcna1-null mice was shown to be mediated by an interaction with the mitochondrial permeability transition (mPT) pore, which when activated triggers the release of calcium and pro-apoptotic factors and eventual cell death (). Previous reports indicated that BHB exerts multiple effects on mitochondria, including increased mitochondrial respiration, enhanced NADH oxidation and ATP production, and reduced reactive oxygen species (ROS) production, all of which either singly or in combination would raise the threshold for mPT (; ; ). Intriguingly, this was the first demonstration that inhibition of mPT could result in anti-seizure effects.
There have been a few additional seminal studies showing the pleiotropic activity of ketone bodies, and while these novel targets were revealed in experimental systems outside the context of epileptic tissues, they nevertheless highlight important molecular actions that have become increasingly relevant in epilepsy research. First, BHB was shown to inhibit histone deacetylases (HDACs) in renal tissue, which resulted in increased resistance to oxidative stress via transcription of antioxidant genes regulated by FOXO3A (Shimazu et al., 2013). The relevance of HDACs in epilepsy is underscored by the fact that the broad-spectrum ASD valproic acid is in part an HDAC inhibitor (). Further, BHB’s neuroprotective properties stem from (among other actions) an interaction with the hydroxycarboxylic acid 2 (HCA2) receptor (or GPR109A, also known as NIACR1 or the niacin receptor 1, and encoded by the HCAR2 gene), a G protein-coupled receptor found on adipocytes, neutrophils, tissue macrophages, and in the anterior cingulate cortex (Rahman et al., 2014). The net effect of BHB binding to HCA2 is a profound anti-inflammatory effect. BHB also targets other key components of the innate immune system. Specifically, it has been shown that BHB prevents the assembly of the innate immune sensor NOD-like receptor protein 3 (NLRP3) inflammasome, a multiprotein complex that induces caspase-1 activation and release of the pro-inflammatory cytokines IL-1β and IL-18 in macrophages (Youm et al., 2015). As neuroinflammation is now unquestionably linked to seizure genesis and epileptogenesis (Vezzani et al., 2015), strategies to mitigate aberrant brain inflammation would be expected to be both anticonvulsant and neuroprotective. Indeed, BHB possesses anti-inflammatory properties, consistent with the fact the KD is highly effective against neuroinflammation-induced epilepsy such as FIRES (febrile infection-related epilepsy syndrome) (). A mechanistic summary of ketone body action illustrated in Figure 2.
Figure 2
2-Deoxyglucose Versus/Plus Ketone Bodies
From the foregoing discussion, it is important to note both 2DG and the KD can suppress seizure activity but likely exert their effects through distinct yet overlapping mechanisms (Table 1). Ketone bodies have also been shown to possess anti-seizure properties, albeit in preclinical models (Simeone et al., 2018). One major distinction between 2DG and the KD is the fact that 2DG does not induce ketosis. And while 2DG and the KD both block seizures in the 6-Hz corneal stimulation and Frings audiogenic seizure susceptible models, 2DG is ineffective in the MES test which models focal-onset seizures with secondary generalization (). Further, despite different induction protocols, the progression of kindling is delayed by both the KD and 2DG (; ; Stafstrom et al., 2009). Thus, while seizure susceptibility is modified by both 2DG and the KD (also ketone bodies) through modulation of biochemical pathways involved in energy metabolism, these interventions do not possess the same anti-seizure profile and cannot be directly compared. That said, the fact that the mechanistic profiles of 2DG and ketone bodies suggest that a combined approach may yield either additive or synergistic effects, especially since a broader spectrum of mechanistic targets and pathways would be influenced. Also, it will be interesting to assess the combined efficacy of 2DG and BHB on seizure control in other chronic epilepsy models with spontaneous seizures such as the pilocarpine and kainate models.
Table 1
| Action and target | References | |
|---|---|---|
| 2-Deoxyglucose | ||
| Inhibition of phosphoglucose isomerase | Wick et al., 1957 | |
| Inhibition of hexokinase | ||
| Decreased expression of BDNF and trkB | ||
| Upregulation of KATP channels | Yang et al., 2013 | |
| Increased tonic GABA inhibition via increased neurosteroidogenesis | ||
| Reduced oxidative stress | ; Yao et al., 2011 | |
| Activation of AMP-kinase | ||
| Disruption of glycosylation | Zhang et al., 2014 | |
| β-Hydroxybutyrate | ||
| Increased mitochondrial biogenesis and ATP production | ; ; | |
| Augmented presynaptic synthesis of GABA | ||
| Inhibition of VGLUT release | ||
| Indirect activation of KATP channels | ||
| Reduced oxidative stress | ; Shimazu et al., 2013 | |
| Raising the threshold for mPT activation | ||
| HDAC inhibition | Shimazu et al., 2013 | |
| Activation of HCA2 receptors | Rahman et al., 2014 | |
| Prevention of NLRP3 inflammasome assembly | Youm et al., 2015 |
Mechanistic comparison between 2-deoxyglucose (2DG) and β-hydroxybutyrate.
Abbreviations: BDNF, brain-derived neurotrophic factor; trkB, Ttropomyosin receptor kinase B; KATP channel, ATP-sensitive potassium channel; GABA, γ-aminobutyric acid; AMP-Kkinase, adenosine monophosphate kinase; VGLUT, vesicular glutamate transporter; mPT, mitochondrial permeability transition; HDAC, histone deacetylase; HCA2, hydroxycarboxylic acid receptor 2; NLRP3, NOD-like receptor protein 3.
Before formulations of 2DG or BHB are approved for clinical use in patients with epilepsy, efficacy and safety need to be clearly demonstrated. In this regard, the relative safety profile of 2DG has already been established in cancer trials (), and epilepsy clinical trials are in progress (). The half-life of 2DG in humans is estimated to be 5–7 h, so this therapy would be potentially useful with twice-daily dosing (). With respect to BHB, ketone esters have been investigated preclinically as potential therapeutic agents, primarily due to their ability to produce prolonged elevations in blood ketone bodies (). However, the pharmacokinetics of BHB have not been carefully studied in humans. While ketone esters have yet to be studied in humans with epilepsy, there is already a medical formulation of MCTs that induces significant ketosis in humans (), and various ketone salts, esters and oils are already widely available through commercial sources and through the Internet. In addition, several metabolites or metabolic strategies have been reported to exhibit potent anticonvulsant actions via alternative mechanisms, including fructose-1,6-bisphosphate (; Shao et al., 2018), decanoic acid (), inhibition of lactate dehydrogenase (Sada et al., 2015), D-leucine (), and polyunsaturated fatty acids (), all of which are worthy of further exploration for epilepsy therapeutics.
Conclusion
Metabolic control of neuronal excitability has increasingly become a worthy scientific paradigm for therapeutic development in the field of epilepsy, impacting key mechanisms in seizure genesis and possibly epileptogenesis. The origin and evolution of this approach have been inspired by the clinical success of the KD and its variants. Within this framework, 2DG and BHB represent two promising approaches for seizure control, the former primarily through partial inhibition of glycolysis and downstream transcriptional regulation, and the latter via pleiotropic actions at mitochondrial, epigenetic and cellular levels. While 2DG and BHB each possesses unique preclinical profiles, both have been shown to reduce seizure susceptibility in several animal models and in multiple in vitro cellular systems.
However, clinical implementation of metabolism-based approaches such as the KD is not without pragmatic challenges regarding administration and patient compliance. Thus, there is a strong need to identify specific metabolic substrates and/or enzymes that might induce clinical benefits comparable to the KD as a necessary condition for rational experimental therapeutics and later clinical validation. 2DG and BHB may only represent component pieces of diet-based treatments for epilepsy, but together, since they recapitulate two core features of the KD (i.e., glycolytic restriction and products of increased fatty acid oxidation), they could in time help validate the concept of a “diet in a pill” (Rho and Sankar, 2008), or polypharmacy in a pill. Of course, the KD induces far broader mechanistic effects than either 2DG or BHB alone (Rogawski et al., 2016), but the current major advantage of these substrates is that they can already be delivered in palatable forms to patients with epilepsy.
Statements
Author contributions
JR, CS, and L-RS wrote the manuscript.
Acknowledgments
JR’s research has been supported by the Canadian Institutes of Health Research. CS’s research has been supported by The Charlie Foundation, the Mathias Koch Memorial Fund of the Community Foundation of Southern Wisconsin, and the Sandra and Malcolm Berman Foundation.
Conflict of interest
We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. JR has served as a paid consultant for Accera Pharma, Xenon Pharmaceuticals, Danone Nutricia, and Ajinomoto USA. CS has served as a paid consultant for Mallinckrodt and has received speaker fees from Nutricia. JR and CS have received royalties from UpToDate for a chapter about the mechanisms of seizures and epilepsy. CS is an inventor on a patent application for the use of 2DG as a clinical antiseizure medication through theWisconsin Alumni Research Foundation. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AallingN. N.NedergaardM.DiNuzzoM. (2018). Cerebral metabolic changes during sleep.Curr. Neurol. Neurosci. Rep.18:57. 10.1007/s11910-018-0868-9
2
BartonM. E.KleinB. D.WolfH. H.WhiteH. S. (2001). Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy.Epilepsy Res.47217–227. 10.1016/s0920-1211(01)00302-3
3
BazzigaluppiP.EbrahimAminiA.WeisspapirI.StefanovicB.CarlenP. L. (2017). Hungry neurons: metabolic insights on seizure dynamics.Int. J. Mol. Sci.18:E2269. 10.3390/ijms18112269
4
BialerM.JohannessenS. I.LevyR. H.PeruccaE.TomsonT.WhiteH. S. (2017). Progress report on new antiepileptic drugs: a summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII).Epilepsia58181–221. 10.1111/epi.13634
5
BoisonD.SteinhäuserC. (2018). Epilepsy and astrocyte energy metabolism.Glia661235–1243. 10.1002/glia.23247
6
BoughK. J.WetheringtonJ.HasselB.PareJ. F.GawrylukJ. W.GreeneJ. G.et al (2006). Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet.Ann. Neurol.60223–235. 10.1002/ana.20899
7
BuchhalterJ. R.D’AlfonsoS.ConnollyM.FungE.MichoulasA.SinasacD.et al (2017). The relationship between D-beta-hydroxybutyrate blood concentrations and seizure control in children treated with the ketogenic diet for medically intractable epilepsy.Epilepsia Open2317–321. 10.1002/epi4.12058
8
CendesF.TheodoreW. H.BrinkmannB. H.SulcV.CascinoG. D. (2016). Neuroimaging of epilepsy.Handb. Clin. Neurol.136985–1014.
9
ChangP.AugustinK.BoddumK.WilliamsS.SunM.TerschakJ. A.et al (2016). Seizure control by decanoic acid through direct AMPA receptor inhibition.Brain139431–443. 10.1093/brain/awv325
10
CheongJ. H.ParkE. S.LiangJ.DennisonJ. B.TsavachidouD.Nguyen-CharlesC.et al (2011). Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.Mol. Cancer Ther.102350–2362. 10.1158/1535-7163.MCT-11-0497
11
CloixJ. F.HévorT. (2009). Epilepsy, regulation of brain energy metabolism and neurotransmission.Curr. Med. Chem.16841–853. 10.2174/092986709787549316
12
D’AgostinoD. P.PillaR.HeldH. E.LandonC. S.PuchowiczM.BrunengraberH.et al (2013). Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats.Am. J. Physiol. Regul. Integr. Comp. Physiol.304R829–R836. 10.1152/ajpregu.00506.2012
13
DaikhinY.YudkoffM. (1998). Ketone bodies and brain glutamate and GABA metabolism.Dev. Neurosci.20358–364. 10.1159/000017331
14
DalléracG.MoulardJ.BenoistJ. F.RouachS.AuvinS.GuilbotA.et al (2017). Non-ketogenic combination of nutritional strategies provides robust protection against seizures.Sci. Rep.7:5496. 10.1038/s41598-017-05542-3
15
de PaduaM. C.DelodiG.VuèetiæM.DurivaultJ.VialV.BayerP.et al (2017). Disrupting glucose-6-phosphate isomerase fully suppresses the “Warburg effect” and activates OXPHOS with minimal impact on tumor growth except in hypoxia.Oncotarget887623–87637. 10.18632/oncotarget.21007
16
DeVivoD. C.LeckieM. P.FerrendelliJ. S.McDougalD. B.Jr. (1978). Chronic ketosis and cerebral metabolism.Ann. Neurol.3331–337. 10.1002/ana.410030410
17
DienelG. A. (2017). Lack of appropriate stoichiometry: strong evidence against an energetically important astrocyte-neuron lactate shuttle in brain.J. Neurosci. Res.952103–2125. 10.1002/jnr.24015
18
DustinS. M.StafstromC. E. (2016). Ketogenic diet, but not polyunsaturated fatty acid diet, reduces spontaneous seizures in juvenile rats with kainic acid-induced epilepsy.J. Epilepsy Res.61–7. 10.14581/jer.16001
19
ElmanI.SokoloffL.AdlerC. M.WeisenfeldN.BreierA. (1999). The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers.Brain Res.815243–249. 10.1016/s0006-8993(98)01137-8
20
ErecinskaM.NelsonD.DaikhinY.YudkoffM. (1996). Regulation of GABA level in rat brain synaptosomes: fluxes through enzymes of the GABA shunt and effects of glutamate, calcium, and ketone bodies.J. Neurochem.672325–2334. 10.1046/j.1471-4159.1996.67062325.x
21
ForteN.MedrihanL.CappettiB.BaldelliP.BenfenatiF. (2016). 2-Deoxy-D-glucose enhances tonic inhibition through the neurosteroid-mediated activation of extrasynaptic GABAA receptors.Epilepsia571987–2000. 10.1111/epi.13578
22
FreemanJ.VeggiottiP.LanziG.TagliabueA.PeruccaE. (2006). The ketogenic diet: from molecular mechanisms to clinical effects.Epilepsy Res.68145–180. 10.1016/j.eplepsyres.2005.10.003
23
FreemanJ. M.ViningE. P.PillasD. J.PyzikP. L.CaseyJ. C.KellyL. M. (1998). The efficacy of the ketogenic diet -: a prospective evaluation of intervention in 150 children.Pediatrics19981358–1363. 10.1542/peds.102.6.1358
24
GanoL. B.PatelM.RhoJ. M. (2014). Ketogenic diets, mitochondria, and neurological diseases.J. Lipid Res.552211–2228. 10.1194/jlr.R048975
25
Garriga-CanutM.SchoenikeB.QaziR.BergendahlK.DaleyT. J.PfenderR. M.et al (2006). 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure.Nat. Neurosci.91382–1387. 10.1038/nn1791
26
GasiorM.YankuraJ.HartmanA. L.FrenchA.RogawskiM. A. (2010). Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose.Epilepsia51385–1394. 10.1111/j.1528-1167.2010.02593.x
27
GilbertD. L.PyzikP. L.FreemanJ. M. (2000). The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.J. Child Neurol.15787–790. 10.1177/088307380001501203
28
GounderM. K.LinH.SteinM.GoodinS.BertinoJ. R.KongA. N.et al (2012). A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma.Biomed. Chromatogr.26650–654. 10.1002/bmc.1710
29
GreeneA. E.TodorovaM. T.SeyfriedT. N. (2003). Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies.J. Neurochem.86529–537. 10.1046/j.1471-4159.2003.01862.x
30
HartmanA. L.LyleM.RogawskiM. A.GasiorM. (2008). Efficacy of the ketogenic diet in the 6-Hz seizure test.Epilepsia49334–339. 10.1111/j.1528-1167.2007.01430.x
31
HartmanA. L.SantosP.O’RiordanK. J.StafstromC. E.HardwickJ. M. (2015). Potent anti-seizure effects of D-leucine.Neurobiol. Dis.8246–53. 10.1016/j.nbd.2015.05.013
32
HeX. P.KotloskiR.NefS.LuikartB. W.ParadaL. F.McNamaraJ. O. (2004). Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model.Neuron4331–42. 10.1016/j.neuron.2004.06.019
33
HendersonS. T.VogelJ. L.BarrL. J.GarvinF.JonesJ. J.CostantiniL. C. (2009). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial.Nutr. Metab.6:31. 10.1186/1743-7075-6-31
34
HöldK. M.SirisomaN. S.IkedaT.NarahashiT.CasidaJ. E. (2000). Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification.Proc. Natl. Acad. Sci. U.S.A.973826–3831. 10.1073/pnas.070042397
35
HoriA.TandonP.HolmesG. L.StafstromC. E. (1997). Ketogenic diet: effects on expression of kindled seizures and behavior in adult rats.Epilepsia38750–758. 10.1111/j.1528-1157.1997.tb01461.x
36
HuX. L.ChengX.FeiJ.XiongZ. Q. (2011). Neuron-restrictive silencer factor is not required for the antiepileptic effect of the ketogenic diet.Epilepsia521609–1616. 10.1111/j.1528-1167.2011.03171.x
37
HuangY. Z.McNamaraJ. O. (2006). Inhibiting glycolysis to reduce seizures: how it might work.Nat. Neurosci.91351–1352. 10.1038/nn1106-1351
38
HuttenlocherP. R. (1976). Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy.Pediatr. Res.10536–540. 10.1203/00006450-197605000-00006
39
IngramD. K.RothG. S. (2011). Glycolytic inhibition as a strategy for developing calorie restriction mimetics.Exp. Gerontol.46148–154. 10.1016/j.exger.2010.12.001
40
IzzoV.Bravo-San PedroJ. M.SicaV.KroemerG.GalluzziL. (2016). Mitochondrial permeability transition: new findings and persisting uncertainties.Trends Cell Biol.26655–667. 10.1016/j.tcb.2016.04.006
41
JugeN.GrayJ. A.OmoteH.MiyajiT.InoueT.HaraC.et al (2010). Metabolic control of vesicular glutamate transport and release.Neuron6899–112. 10.1016/j.neuron.2010.09.002
42
KawamuraM.Jr.RuskinD. N.MasinoS. A. (2010). Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors, and KATP channels.J. Neurosci.303886–3895. 10.1523/JNEUROSCI.0055-10.2010
43
KawamuraM.Jr.RuskinD. N.MasinoS. A. (2016). Metabolic therapy for temporal lobe epilepsy in a dish: investigating mechanisms of ketogenic diet using electrophysiological recordings in hippocampal slices.Front. Mol. Neurosci.9:112. 10.3389/fnmol.2016.00112
44
KeithH. M. (1931). The effect of various factors on experimentally produced convulsions.Am. J. Dis. Child41532–543.
45
KeithH. M. (1932). Further studies of the control of experimentally produced convulsions.Pharmacol. Exp. Ther.44449–455.
46
KeithH. M. (1933). Factors influencing experimentally produced convulsions.Arch. Neurol. Psychiatry29148–154.
47
KeithH. M. (1935). Experimental convulsions induced by administration of thujone.Arch. Neurol. Psychiatry341022–1040.
48
KimD. Y.SimeoneK. A.SimeoneT. A.PandyaJ. D.WilkeJ. C.AhnY.et al (2015). Ketone bodies mediate antiseizure effects through mitochondrial permeability transition.Ann. Neurol.7877–87. 10.1002/ana.24424
49
KimD. Y.VallejoJ.RhoJ. M. (2010). Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors.J. Neurochem.114130–141. 10.1111/j.1471-4159.2010.06728.x
50
LambrechtsD. A.de KinderenR. J.VlesJ. S.de LouwA. J.AldenkampA. P.MajoieH. J. (2017). A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy.Acta Neurol. Scand.135231–239. 10.1111/ane.12592
51
LeeJ.Bruce-KellerA. J.KrumanY.ChanS. L.MattsonM. P. (1999). 2-Deoxy-D-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins.J. Neurosci. Res.5748–61. 10.1002/(sici)1097-4547(19990701)57:1<48::aid-jnr6>3.3.co;2-c
52
LianX. Y.KhanF. A.StringerJ. L. (2007). Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.J. Neurosci.2712007–12011. 10.1523/jneurosci.3163-07.2007
53
LibrizziL.de CurtisM.JanigroD.RuntzL.de BockF.BarbierE. L.et al (2018). Cerebrovascular heterogeneity and neuronal excitability.Neurosci. Lett.66775–83. 10.1016/j.neulet.2017.01.013
54
LikhodiiS. S.SerbanescuI.CortezM. A.MurphyP.SneadO. C.IIIBurnhamW. M. (2003). Anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet.Ann. Neurol.54219–226. 10.1002/ana.10634
55
LundT. M.ObelL. F.RisaO.SonnewaldU. (2011). Beta-Hydroxybutyrate is the preferred substrate for GABA and glutamate synthesis while glucose is indispensable during depolarization in cultured GABAergic neurons.Neurochem. Int.59309–318. 10.1016/j.neuint.2011.06.002
56
LundT. M.RisaO.SonnewaldU.SchousboeA.WaagepetersenH. S. (2009). Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons.J. Neurochem.11080–91. 10.1111/j.1471-4159.2009.06115.x
57
LutasA.YellenG. (2013). The ketogenic diet: metabolic influences on brain excitability and epilepsy.Trends Neurosci.3632–40. 10.1016/j.tins.2012.11.005
58
MaW.BergJ.YellenG. (2007). Ketogenic diet metabolites reduce firing in central neurons by opening KATP channels.J. Neurosci.273618–3625. 10.1523/jneurosci.0132-07.2007
59
MaaloufM.RhoJ. M. (2008). Oxidative impairment of hippocampal long-term potentiation involves activation of protein phosphatase 2A and is prevented by ketone bodies.J. Neurosci. Res.863322–3330. 10.1002/jnr.21782
60
MaaloufM.SullivanP. G.DavisL.KimD. Y.RhoJ. M. (2007). Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation.Neuroscience145256–264. 10.1016/j.neuroscience.2006.11.065
61
MagistrettiP. J.AllamanI. (2015). A cellular perspective on brain energy metabolism and functional imaging.Neuron86883–901. 10.1016/j.neuron.2015.03.035
62
MergenthalerP.LindauerU.DienelG. A.MeiselA. (2013). Sugar for the brain: the role of glucose in physiological and pathological brain function.Trends Neurosci.36587–597. 10.1016/j.tins.2013.07.001
63
MinlebaevM.KhazipovR. (2011). Antiepileptic effects of endogenous beta-hydroxybutyrate in suckling infant rats.Epilepsy Res.95100–109. 10.1016/j.eplepsyres.2011.03.003
64
MontiB.PolazziE.ContestabileA. (2009). Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.Curr. Mol. Pharmacol.295–109. 10.2174/1874467210902010095
65
NabboutR.MazzucaM.HubertP.PeudennierS.AllaireC.FlurinV.et al (2010). Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES).Epilepsia512033–2037. 10.1111/j.1528-1167.2010.02703.x
66
NealE. G.ChaffeH.SchwartzR. H.LawsonM. S.EdwardsN.FitzsimmonsG.et al (2008). The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial.Lancet Neurol.7500–506. 10.1016/S1474-4422(08)70092-9
67
NealE. G.ChaffeH.SchwartzR. H.LawsonM. S.EdwardsN.FitzsimmonsG.et al (2009). A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy.Epilepsia501109–1117. 10.1111/j.1528-1167.2008.01870.x
68
NedergaardS.AndreasenM. (2018). Opposing effects of 2-deoxy-D-glucose on interictal- and ictal-like activity when K+ currents and GABAA receptors are blocked in rat hippocampus in vitro.J. Neurophysiol.1191912–1923. 10.1152/jn.00732.2017
69
PaniG. (2015). Neuroprotective effects of dietary restriction: evidence and mechanisms.Semin. Cell Dev. Biol.40106–114. 10.1016/j.semcdb.2015.03.004
70
ParkM.SongK. S.KimH. K.ParkY. J.KimH. S.BaeM. I.et al (2009). 2-Deoxy-D-glucose protects neural progenitor cells against oxidative stress through the activation of AMP-activated protein kinase.Neurosci. Lett.449201–206. 10.1016/j.neulet.2008.11.007
71
PelicanoH.MartinD. S.XuR.-H.HuangP. (2006). Glycolysis inhibition for anticancer treatment.Oncogene254633–4646. 10.1038/sj.onc.1209597
72
PellerinL.MagistrettiP. J. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization.Proc. Natl. Acad. Sci. U.S.A.9110625–10629. 10.1073/pnas.91.22.10625
73
PfeiferH. H.ThieleE. A. (2005). Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy.Neurology651810–1812. 10.1212/01.wnl.0000187071.24292.9e
74
RahmanM.MuhammadS.KhanM. A.ChenH.RidderD. A.Muller-FielitzH.et al (2014). The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages.Nat. Commun.5:3944. 10.1038/ncomms4944
75
RedjakK.RedjakR.Sieklucka-DziubaM.StelmasiakZ.GriebP. (2001). 2-Deoxyglucose enhances epileptic tolerance evoked by transient incomplete brain ischemia in mice.Epilepsy Res.43271–278. 10.1016/s0920-1211(01)00184-x
76
ReidC. A.MullenS.KimT. H.PetrouS. (2014). Epilepsy, energy deficiency and new therapeutic approaches including diet.Pharmacol. Ther.144192–201. 10.1016/j.pharmthera.2014.06.001
77
RhoJ. M.AndersonG. D.DonevanS. D.WhiteH. S. (2002). Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo.Epilepsia43358–361. 10.1046/j.1528-1157.2002.47901.x
78
RhoJ. M.SankarR. (2008). The ketogenic diet in a pill: is this possible?Epilepsia49(Suppl. 8), 127–133. 10.1111/j.1528-1167.2008.01857.x
79
RhoJ. M.StafstromC. E. (2012). The ketogenic diet: what has science taught us?Epilepsy Res.100210–217. 10.1016/j.eplepsyres.2011.05.021
80
RogawskiM. A.LoscherW.RhoJ. M. (2016). Mechanisms of action of antiseizure drugs and the ketogenic diet.Cold Spring Harb. Perspect. Med.6:a022780. 10.1101/cshperspect.a022780
81
SadaN.LeeS.KatsuT.OtsukiT.InoueT. (2015). Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy.Science3471362–1367. 10.1126/science.aaa1299
82
SamokhinaE.PopovaI.MalkovA.IvanovA. I.PapadiaD.OsypovA.et al (2017). Chronic inhibition of brain glycolysis initiates epileptogenesis.J. Neurosci. Res.952195–2206. 10.1002/jnr.24019
83
SchwartzkroinP. A. (1999). Mechanisms underlying the anti-epileptic efficacy of the ketogenic diet.Epilepsy Res.37171–180. 10.1016/s0920-1211(99)00069-8
84
ShaoL. R.StafstromC. E. (2017). Glycolytic inhibition by 2-deoxy-D-glucose abolishes both neuronal and network bursts in an in vitro seizure model.J. Neurophysiol.118103–113. 10.1152/jn.00100.2017
85
ShaoL. R.WangG.StafstromC. E. (2018). The glycolytic metabolite, fructose-1,6-bisphosphate, blocks epileptiform bursts by attenuating voltage-activated calcium currents in hippocampal slices.Front. Cell. Neurosci.12:168. 10.3389/fncel.2018.00168
86
ShimazuT.HirscheyM. D.NewmanJ.HeW.ShirakawaK.Le MoanN.et al (2013). Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor.Science339211–214. 10.1126/science.1227166
87
SimeoneT. A.SimeoneK. A.StafstromC. E.RhoJ. M. (2018). Do ketone bodies mediate the anti-seizure effects of the ketogenic diet?Neuropharmacology133233–241. 10.1016/j.neuropharm.2018.01.011
88
StafstromC. E.OckulyJ. C.MurphreeL.ValleyM. T.RoopraA.SutulaT. P. (2009). Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models.Ann. Neurol.65435–447. 10.1002/ana.21603
89
ThavendiranathanP.MendoncaA.DellC.LikhodiiS. S.MusaK.IracleousC.et al (2000). The MCT ketogenic diet: effects on animal seizure models.Exp. Neurol.161696–703. 10.1006/exnr.1999.7298
90
ThioL. L.WongM.YamadaK. A. (2000). Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission.Neurology54325–331.
91
Valente-SilvaP.LemosC.KofalviA.CunhaR. A.JonesJ. G. (2015). Ketone bodies effectively compete with glucose for neuronal acetyl-CoA generation in rat hippocampal slices.NMR Biomed.281111–1116. 10.1002/nbm.3355
92
van DelftR.LambrechtsD.VerschuureP.HulsmanJ.MajoieM. (2010). Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine.Seizure1936–39. 10.1016/j.seizure.2009.10.009
93
VezzaniA.LangB.AronicaE. (2015). Immunity and inflammation in epilepsy.Cold Spring Harb. Perspect. Med.6:a022699. 10.1101/cshperspect.a022699
94
WickA. N.DruryD. R.NakadaH. I.WolfJ. B. (1957). Localization of the primary metabolic block produced by 2-deoxyglucose.J. Biol. Chem.224963–969.
95
WreeA. (1990). Principles of the 2-deoxyglucose method for the determination of the local cerebral glucose utilization.Eur. J. Morphol.28132–138.
96
YangH.GuoR.WuJ.PengY.XieD.ZhengW.et al (2013). The antiepileptic effect of the glycolytic inhibitor 2-deoxy-D-glucose is mediated by upregulation of KATP channel subunits Kir6.1 and Kir6.2.Neurochem. Res.38677–685. 10.1007/s11064-012-0958-z
97
YangL.ZhaoJ.MilutinovicP. S.BrosnanR. J.EgerE. I.IISonnerJ. M. (2007). Anesthetic properties of the ketone bodies beta-hydroxybutyric acid and acetone.Anesth. Analg.105673–679. 10.1213/01.ane.0000278127.68312.dc
98
YaoJ.ChenS.MaoZ.CadenasE.BrintonR. D. (2011). 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer’s disease.PLoS One6:e21788. 10.1371/journal.pone.0021788
99
YoumY. H.NguyenK. Y.GrantR. W.GoldbergE. L.BodogaiM.KimD.et al (2015). The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.Nat. Med.21263–269. 10.1038/nm.3804
100
YudkoffM.DaikhinY.NissimI.LazarowA.NissimI. (2001). Brain amino acid metabolism and ketosis.J. Neurosci. Res.66272–281. 10.1002/jnr.1221
101
YuenA. W. C.SanderJ. W. (2014). Rationale for using intermittent calorie restriction as a dietary treatment for drug resistant epilepsy.Epilepsy Behav.33110–114. 10.1016/j.yebeh.2014.02.026
102
YumM. S.LeeM.WooD. C.KimD. W.KoT. S.VelisekL. (2015). Beta-Hydroxybutyrate attenuates NMDA-induced spasms in rats with evidence of neuronal stabilization on MR spectroscopy.Epilepsy Res.117125–132. 10.1016/j.eplepsyres.2015.08.005
103
ZhangD.LiJ.WangF.HuJ.WangS.SunY. (2014). 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy.Cancer Lett.355176–183. 10.1016/j.canlet.2014.09.003
104
ZhangY.ZhangS.Marin-ValenciaI.PuchowiczM. A. (2015). Decreased carbon shunting from glucose toward oxidative metabolism in diet-induced ketotic rat brain.J. Neurochem.132301–312. 10.1111/jnc.12965
Summary
Keywords
epilepsy, 2-deoxyglucose (2DG), glycolysis, ketosis, ketone body, beta-hydroxybutyrate, ketogenic diet, metabolic therapy
Citation
Rho JM, Shao L-R and Stafstrom CE (2019) 2-Deoxyglucose and Beta-Hydroxybutyrate: Metabolic Agents for Seizure Control. Front. Cell. Neurosci. 13:172. doi: 10.3389/fncel.2019.00172
Received
20 July 2018
Accepted
11 April 2019
Published
30 April 2019
Volume
13 - 2019
Edited by
Antonio Gambardella, Università degli Studi “Magna Græcia” di Catanzaro, Italy
Reviewed by
Ursula Susan Sandau, Oregon Health & Science University, United States; Mauro DiNuzzo, Independent Researcher, Rome, Italy
Updates
Copyright
© 2019 Rho, Shao and Stafstrom.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jong M. Rho, jong.rho@ahs.ca
This article was submitted to Cellular Neuropathology, a section of the journal Frontiers in Cellular Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.